Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients

Annals of Surgical Oncology

Volumn 15, Issue 1, 2008, Pages 69-79

  Lieto, Eva ^a   Ferraraccio, Francesca ^a   Orditura, Michele ^a   Castellano, Paolo ^a   Mura, Anna La ^a   Pinto, Margherita ^a   Zamboli, Anna ^a   De Vita, Ferdinando ^a   Galizia, Gennaro ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Epidermal growth factor receptor; Gastric cancer; Prognostic factors; Targeted biological therapy; Vascular endothelial growth factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN;

ACCURACY; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; STOMACH CANCER; STOMACH MUCOSA; SURVIVAL RATE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38049177080     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9596-0     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics. CA Cancer J Clin 2006; 56:106-130
2. Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2:98-107
3. Hartgrink HH, van de Velde CJ. Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer. J Surg Oncol 2005; 90:153-165
4. Novotny AR, Schuhmacher C, Bush R, Kattan MW, Brennan MF, Siewert JR. Predicting individual survival after gastric cancer resection: validation of a US-derived nomogram at a single high-volume center in Europe. Ann Surg 2006; 243:74-81
5. Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005; 23:1237-1244
6. Allal AS, Zwahlen D, Brundler MA, de Peyer R, Morel P, Huber O, Roth AD. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 2005; 63:1286-1289
7. Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63:1279-1285
8. MacDonald JS. Gastric cancer - new therapeutic options. N Engl J Med 2006; 355:76-77
9. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11-20
10. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized duthc gastric cancer group trial. J Clin Oncol 2004; 22:2069-2077
11. Hundahl SA, Wanebo HJ. Changing gastric cancer treatment in the United States and the pursuit of quality. Eur J Surg Oncol 2005; 31:605-615
12. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and a meta-analysis based on aggregate data. J Clin Oncol 2006; 24:2903-2909
13. Chong G, Cunningham D. Gastrointestinal cancer: recent developments in medical oncology. Eur J Surg Oncol 2005; 31:453-460
14. Sutter AP, Zeitz M, Scherübl H. Recent results in understanding molecular patways in the medical treatment of esophageal and gastric cancer. Onkologie 2004; 27:17-21
15. Jüttner S, Wißmann C, Jöns T, et al. Vascular endothelial growth factor-D and ist receptor VEGF-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24:228-239
16. Wang TB, Deng MH, Qiu WS, Dong WG. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 2007; 13:1794-1798
17. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23:2445-2459
18. Tzanakis N, Gazouli M, Rallis G, et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol 2006; 94:624-630
19. Ding S, Li C, Lin S, et al. Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma. Oncol Rep 2007; 17:369-375
20. Saito H, Osaki T, Murakami D, et al. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol 2007; 95:123-128
21. Kondo K, Kaneko T, Baba M, Konno H. VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer. Biol Pharm Bull 2007; 30:633-637
22. Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007; 31:1458-1468
23. Boku N, Ohtsu A, Yoshida S, et al. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn J Clin Oncol 2007; 37:275-281
24. Fondevila C, Metges JP, Fuster JJ, et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 2004; 90:206-215
25. Lang SA, Klein D, Moser C, et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 2007; 6:1123-1132
26. Ito R, Nakayama H, Yoshida K, Matsumura S, Oda N, Yasui W. Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma. Virchows Arch 2004; 444:324-331
27. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-2799
28. Romano M, Ricci V, Zarrilli R. Mechanisms of disease: Helicobacter pylori-related gastric carcinogenesis-implications for chemoprevention. Nat Clin Pract Gastroenterol Hepatol 2006; 3:622-632
29. Grogg KL, Lohse CM, Pankratz VS, Halling KC, Smyrk TC. Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod Pathol 2003; 16:641-651
30. Hiyama T, Tanaka S, Yoshihara M, et al. Chromosomal and microsatellite instability in sporadic gastric cancer. J Gastroenterol Hepatol 2004; 19:756-760
31. th Edition. Ed. Springer-Verlag., pp.99-106, 2002
32. Galizia G, Lieto E, Ferrarraccio F, et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004; 10:3490-3499
33. Galizia G, Lieto E, Ferrarraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006; 13:823-835
34. Chan YH. Biostatistics 203. Survival analysis. Singapore Med J 2004; 45:249-256
35. Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931-939
36. Bonavida B. Preface: antibody therapy for cancer. Oncogene 2007; 26:3592-3593
37. McCarty MF, Wey J, Stoeltzing O, et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004; 3:1041-1048
38. Ciardiello F, Troiani T, Bianco R, et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 2006; 17(suppl_7):vii109-vii114